2013
Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides
Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. Journal Of The American Academy Of Dermatology 2013, 69: 537-543. PMID: 23849563, DOI: 10.1016/j.jaad.2013.04.063.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAge FactorsAgedAnalysis of VarianceCohort StudiesDermatomycosesDose Fractionation, RadiationDose-Response Relationship, RadiationElectronsFemaleHumansIncidenceMaleMiddle AgedMultivariate AnalysisMycosis FungoidesNeoplasm InvasivenessNeoplasm StagingPrognosisRadiodermatitisRadiotherapy DosageRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex FactorsSkin Diseases, BacterialSkin NeoplasmsWhole-Body IrradiationConceptsTotal skin electron beam therapyMycosis fungoidesSkin infectionsElectron beam therapyAcute toxicityBeam therapyAcute treatment toxicityRetrospective study designIncidence of infectionRisk of infectionCommon toxicitiesTreatment toxicityCutaneous infectionsSkin painBaseline incidenceToxicity gradeGrade 3Modern seriesGrade 2Grade 1Consecutive coursesFungoidesInfectionStudy designGrade 4
2011
The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers
Chen Z, Roberts K, Decker R, Pathare P, Rockwell S, Nath R. The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers. Physics In Medicine And Biology 2011, 56: 4895-4912. PMID: 21772076, PMCID: PMC3154133, DOI: 10.1088/0031-9155/56/15/016.Peer-Reviewed Original ResearchConceptsPermanent interstitial brachytherapyProstate edemaProstate cancerEffects of edemaTumor control probabilityImpact of edemaInterstitial brachytherapyCell survivalEarly-stage prostate cancerControl probabilityStage prostate cancerCurrent clinical practiceProstate cancer cellsTumor cell proliferationInterstitial brachytherapy treatmentSublethal damage repairDose variationTumor cell survivalTumor characteristicsTumor controlClinical impactEdemaEdema evolutionClinical practiceProstate gland
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue bedsCombined use of transverse and scout computed tomography scans to localize radioactive seeds in an interstitial brachytherapy implant
Yue N, Chen Z, Bond J, Son Y, Nath R. Combined use of transverse and scout computed tomography scans to localize radioactive seeds in an interstitial brachytherapy implant. Medical Physics 1999, 26: 502-505. PMID: 10227350, DOI: 10.1118/1.598548.Peer-Reviewed Original Research
1998
Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants
Nath R, Roberts K, Ng M, Peschel R, Chen Z. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants. Medical Physics 1998, 25: 2293-2307. PMID: 9874821, DOI: 10.1118/1.598440.Peer-Reviewed Original ResearchConceptsSurvival rateProstate cancerInterstitial implantsLocal recurrence-free survival rateRecurrence-free survival ratesLocal control rateLocal tumor controlExcellent clinical resultsProstate cancer patientsUnfavorable groupClinical efficacyCancer patientsControl rateTumor controlClinical resultsFavorable groupDose coveragePatientsDosimetric parametersDosimetry parametersIsodose surfaceSignificant differencesVirginia studyUnfavorable parametersCancer